Table 6 Summary of active clinical trials applying vaccinal and oncolytic virus strategies
NCT number | Agent/Drug | Vaccine type | Combination drug/s | Phase | Mechanism | Primary outcome | Status |
|---|---|---|---|---|---|---|---|
NCT02950766 | NeoVax | Peptide-based | Ipilimumab | I | Personalised neoantigen vaccine | Safety, dose | Recruiting |
NCT03715985 | EVAX-01-CAF09b | Peptide-based | anti-PD-1, anti-PD-L1 | I | Safety, efficacy | Recruiting | |
NCT00458536 | DC tumour fusion | Dendritic cell | GM-CSF | I/II | Improving antigen presentation | Safety | Active not recruiting |
NCT03548467 | VB10.NEO | DNA Plasmid | Bempegaldesleukin | I/II | Improved immune response elicited by CD4+ and CD8+ T cells | Safety | Recruiting |
NCT03633110 | GEN-009 | Autologous | Nivolumab/Pembrolizumab | I/II | Elicit CD8+ T cell response | Safety | Active not recruiting |
NCT03294083 | Pexa-Vec | Oncolytic vaccinia virus | REGN2819 | I | Stimulate immune response, replicates in and lyses tumour cells | ORR, safety, dose | Recruiting |